GlassScriptPhysician profile
Ani Pavli
NPI 1124620604
$13,878.64
in general payments reported to CMS, 2019-2025
42 companies · $2,046 in 2025
The $2,046 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,592 · 2022: $3,109 · 2023: $3,195 · 2024: $2,935 · 2025: $2,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,176.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,990.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,415.00 | 2021-2025 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $946.38 | 2021-2025 | Rybelsus, Ozempic, Saxenda |
| Astellas Pharma US INC | $774.01 | 2021-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $681.33 | 2021-2024 | Trulance, Uceris, Xifaxan |
| Pfizer INC. | $661.98 | 2023-2025 | |
| Glaxosmithkline, LLC. | $585.33 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $484.79 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $459.17 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $429.78 | 2021-2024 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.66 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $409.11 | 2021-2025 | |
| Lilly USA, LLC | $351.79 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Phathom Pharmaceuticals, INC. | $184.04 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $162.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ani Pavli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.